Our results demonstrated that silencing MeCP2 significantly inhibited breast cancer cell proliferation and impeded tumor growth as well as repressed cell growth by blocking G1–S cell cycle transition through regulating CDK2, P53, and P2122–27, which are cell cycle-regulatory genes involved in tumor carcinogenesis and proliferation28,29. The gene discussed is TP53; the disease is breast carcinoma.